Do you want to read an article? Please log in or register.
Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation
Lung Cancer
Related content
Lung Cancer
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
Clin Lung Cancer
Masuda T, Katsumata S, Isaka M, Serizawa M, Kawata T, Asami M, Yamaguchi D, Matsushima K, Hayasaka K, Kojima H, Yokomakura N, Konno H, Nagashima T, Urakami K, Yamaguchi K, Ohde Y
doi: 10.1016/j.cllc.2025.04.009
RECOMMENDED
Lung Cancer
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A
doi: 10.1016/j.cllc.2025.06.005
Lung Cancer
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Eur J Cancer
Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS
doi: 10.1016/j.ejca.2026.116744
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
RECOMMENDED
Lung Cancer
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T
doi: 10.1016/j.lungcan.2025.108671
Lung Cancer
Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy
Lung Cancer
Guijosa A, Rios-Garcia E, Dávila-Dupont D, Cruz-Rico G, Russo A, Cabrera Miranda LA, Cardona AF, Rolfo C, Arrieta O
doi: 10.1016/j.lungcan.2025.108722
Lung Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
Lung Cancer
Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Clin Lung Cancer
Nakamura M, Kageyama SI, Hirata H, Ohira M, Sakai SA, Hakozaki Y, Hojo H, Fujisawa T, Yamashita R, Haeno H, Kanai A, Suzuki Y, Yamaguchi M, Tsuchihara K, Zenda S
doi: 10.1016/j.cllc.2025.09.013
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015